For this purpose, we used syngeneic tumor models in immunocompetent mice, and we were able to validate several clinical observations in these mice, including the daratumumab-mediated elimination of CD38+ Tregs and CD38+ MDSCs [12,13,15]. This evidence concerns the gene CD38 and neoplasm.